[Featured Stock] Celltrion, Merger Completed + Takeda Sells Asia-Pacific Distribution Rights, Gains Hundreds of Billions KRW...

Celltrion is showing strong performance. Following the completion of its merger with Celltrion Healthcare and ahead of the listing of the integrated Celltrion scheduled for the 12th, buying momentum is gathering. Additionally, news that it sold the Asian-Pacific pharmaceutical rights of Japan's Takeda Pharmaceutical for a profit of several hundred billion won is also believed to have influenced this trend.

As of 10:28 AM on the 2nd, Celltrion is trading at 220,000 KRW, up 9.18% compared to the previous day.

On the 28th of last month, Celltrion and Celltrion Healthcare completed their merger. The listing date for the integrated Celltrion is set for the 12th. Daishin Securities projected in its '2024 Industry Outlook' report that the merged Celltrion's consolidated revenue for the new year will be 3.6723 trillion KRW, with an operating profit of 1.513 trillion KRW.

Lee Hee-young, a researcher at Daishin Securities, explained, "The merger will enable enhanced transparency through simplification of the transaction structure and secure cost competitiveness through improved cost ratios," adding, "The integrated resources from the merger also open up possibilities for large-scale investments."

On the same day, it was reported that the Celltrion Group is selling the Asian-Pacific pharmaceutical rights of Japan's Takeda Pharmaceutical to CBC Group, a Chinese bio-healthcare investment firm and the largest in Asia. CBC Group manages assets worth $7 billion (approximately 9.1 trillion KRW), making it the largest specialized bio-healthcare investment company in Asia.

With improved cash liquidity from this sale, the Celltrion Group is expected to use the funds for new pipeline clinical trials or mergers and acquisitions (M&A). Analysts also suggest that this will accelerate their biosimilar and new drug development projects.

This content was produced with the assistance of AI translation services.